Claims
- 1. A method for detecting the presence of ovarian cancer in a patient, comprising the steps of:
(a) obtaining a biological sample from a patient; (b) contacting the biological sample with an oligonucleotide that hybridizes to a sequence set forth in any one of SEQ ID NO: 1-10,912 under highly stringent conditions; (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and (d) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom detecting the presence of ovarian cancer in the patient.
- 2. The method of claim 1, wherein said sequence is selected from a sequence set forth in any one of SEQ ID NO: 10863-10912.
- 3. The method of claim 1, wherein said sequence is selected from a sequence set forth in any one of SEQ ID NO: 10864-10869, 10872-10878, 10880-10884 and 10894-10895.
- 4. The method of claim 1, wherein said detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide is performed by a polymerase chain reaction.
- 5. The method of claim 1, wherein the biological sample is selected from the group consisting of serum and ovarian tissue.
- 6. An oligonucleotide useful in the detection of ovarian cancer in a patient, wherein said oligonucleotide hybridizes to a sequence set forth in any one of SEQ ID NO: 1-10,912 under highly stringent conditions.
- 7. A diagnostic kit comprising at least one oligonucleotide according to claim 6.
- 8. A method for detecting the presence of a cancer in a patient, comprising the steps of:
(a) obtaining a biological sample from a patient; (b) contacting the biological sample with a binding agent that binds to a polypeptide selected from the group consisting of:
(i) a polypeptide encoded by a polynucleotide sequence set forth in any one of SEQ ID NO: 1-10,912; (ii) a sequence having at least 90% identity to said polypeptide; (iii) a sequence having at least 95% identity to said polypeptide; (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom detecting the presence of a cancer in the patient.
- 9. A method for stimulating and/or expanding T cells specific for an ovarian tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:
(a) a polypeptide sequence selected from the group consisting of:
(i) a polypeptide encoded by a polynucleotide sequence set forth in any one of SEQ ID NO: 1-10,912; (ii) a sequence having at least 90% identity to said polypeptide; (iii) a sequence having at least 95% identity to said polypeptide; (b) a polynucleotide selected from the group consisting of:
(i) a sequence set forth in any one of SEQ ID NO: 1-10,912; (ii) a complement of a sequence set forth in any one of SEQ ID NO: 1-10,912; (iii) a sequence consisting of at least 20 contiguous residues of a sequence set forth in any one of SEQ ID NO: 1-10,912; (iv) a sequence that hybridizes to a sequence set forth in any one of SEQ ID NO: 1-10,912, under highly stringent conditions; (v) a sequence having at least 90% identity to a sequence set forth in any one of SEQ ID NO: 1-10,912; and (vi) a sequence having at least 95% identity to a sequence set forth in any one of SEQ ID NO: 1-10,912.
- 10. An isolated T cell population, comprising T cells prepared according to the method of claim 9.
- 11. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:
(a) a polypeptide sequence selected from the group consisting of:
(i) a polypeptide encoded by a polynucleotide sequence set forth in any one of SEQ ID NO: 1-10,912; (ii) a sequence having at least 90% identity to said polypeptide; (iii) a sequence having at least 95% identity to said polypeptide; (b) a polynucleotide sequence selected from the group consisting of:
(i) a sequence set forth in any one of SEQ ID NO: 1-10,912; (ii) a complement of a sequence set forth in any one of SEQ ID NO: 1-10,912; (iii) a sequence consisting of at least 20 contiguous residues of a sequence set forth in any one of SEQ ID NO: 1-10,912; (iv) a sequence that hybridizes to a sequence set forth in any one of SEQ ID NO: 1-10,912 under highly stringent conditions; (v) a sequence having at least 95% identity to a sequence set forth in any one of SEQ ID NO: 1-10,912; (vi) a degenerate variant of a sequence set forth in any one of SEQ ID NO: 1-10,912; (c) a T cell population according to claim 10; and (d) antigen presenting cells that express a polypeptide selected from the group consisting of:
(i) a polypeptide encoded by a polynucleotide sequence set forth in any one of SEQ ID NO: 1-10,912. (ii) a sequence having at least 90% identity to said polypeptide; and (iii) a sequence having at least 95% identity to said polypeptide.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is related to U.S. Provisional Application No. 60/207,484 filed on May 26, 2000, which is incorporated in its entirety herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60207484 |
May 2000 |
US |